Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal Carcinoma
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.
Recurrent Nasopharyngeal Carcinoma
DRUG: PD-1 blocking antibody|DRUG: Chemotherapy|RADIATION: IMRT
Overall survival, From date of recruitment to death, 2 years
Objective response rate, Patient's short-term effect, After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days)|Disease control rate, Patient's short-term effect, After 3 cycles of GP chemothrapy plus PD-1 antibody (each cycle is 21 days)|Progression free survival, From date of recruitment to disease progression or death, 2 years|Adverse effects, Evaluating with CTCAE v5.0, through study completion, an average of 3 months|Quality of life: EuroQoL 5 dimension, Evaluating with questionnaire of EuroQoL 5 dimension, 5 level health state utility index (EQ-5D-5L), through whole study, an average of 2 years
This is a a prospective, single-arm phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of PD-1 antibody with chemotherapy in high-risk recurrent nasopharyngeal carcinoma.